{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001367644","name":"Emergent BioSolutions Inc.","summary":"Emergent BioSolutions is a global life sciences company providing preparedness and response solutions for public health threats including CBRNE, emerging infectious diseases, and opioid overdose emergencies. Its portfolio includes 11 products such as NARCAN Nasal Spray, KLOXXADO, BioThrax, CYFENDUS, ACAM2000, ANTHRASIL, BAT, Ebanga, and raxibacumab. Revenue comes from commercial product sales, government MCM procurement, CDMO bioservices, and R&D contracts and grants from third-party sources.","people":[],"products":[{"name":"NARCAN Nasal Spray","type":"hardware","description":"OTC naloxone HCl nasal spray for opioid overdose reversal, sold at retail pharmacies and through government/community channels."},{"name":"KLOXXADO Nasal Spray","type":"hardware","description":"Prescription naloxone HCl 8mg nasal spray for opioid overdose, sold at pharmacies and public/government entities."},{"name":"BioThrax (Anthrax Vaccine Adsorbed)","type":"hardware","description":"FDA-approved vaccine for pre- and post-exposure prophylaxis against Bacillus anthracis in persons 18-65 years old."},{"name":"CYFENDUS (Anthrax Vaccine Adsorbed Adjuvanted)","type":"hardware","description":"FDA-approved vaccine for post-exposure prophylaxis against Bacillus anthracis in persons 18-65 years old."},{"name":"ACAM2000 (Smallpox and Mpox Vaccine, Live)","type":"hardware","description":"FDA-approved live vaccinia vaccine for active immunization against smallpox and mpox in high-risk individuals."},{"name":"ANTHRASIL","type":"hardware","description":"FDA/Canada-approved anthrax immune globulin for treatment of inhalational anthrax combined with antibacterials."},{"name":"BAT (Botulism Antitoxin Heptavalent)","type":"hardware","description":"Approved heptavalent equine antitoxin for treatment of symptomatic botulism in adults and pediatric patients."},{"name":"Ebanga (ansuvimab-zykl)","type":"hardware","description":"FDA-approved injection for treatment of Orthoebolavirus zairense infection in adults, pediatric patients, and neonates."},{"name":"Raxibacumab","type":"hardware","description":"FDA-approved injection for treatment of inhalational anthrax due to Bacillus anthracis combined with antibiotics."},{"name":"CNJ-016 (VIGIV)","type":"hardware","description":"MCM product under government contract for treatment related to smallpox vaccination complications."},{"name":"TEMBEXA","type":"hardware","description":"MCM product under government contract; smallpox antiviral medical countermeasure."}],"partnerships":[{"partner_name":"Bavarian Nordic","partnership_type":"strategic","description":"Sold travel health business including Vivotif, Vaxchora, CHIKV VLP, and manufacturing sites; milestone and earn-out payments up to $110M total.","start_date":null},{"partner_name":"Syngene International","partnership_type":"strategic","description":"Sold Baltimore-Bayview drug substance manufacturing facility for ~$36.5M; retained rights to secure manufacturing services at the facility.","start_date":null},{"partner_name":"Hikma","partnership_type":"licensing","description":"Acquired exclusive commercial rights in the U.S. and Canada to KLOXXADO (naloxone HCl) Nasal Spray 8mg.","start_date":null},{"partner_name":"SERB Pharmaceuticals / BTG International Inc.","partnership_type":"strategic","description":"Sold worldwide rights to RSDL (Reactive Skin Decontamination Lotion) via Stock and Asset Purchase Agreement in July 2024.","start_date":null},{"partner_name":"Bora Pharmaceuticals Injectables Inc.","partnership_type":"strategic","description":"Sold Drug Product facility in Baltimore-Camden as part of manufacturing footprint restructuring.","start_date":null},{"partner_name":"Swiss Rockets Ltd.","partnership_type":"strategic","description":"Strategic innovation investment made during 2025 as part of the Company's innovation initiative.","start_date":null},{"partner_name":"OHA Agency LLC","partnership_type":"strategic","description":"Administrative agent under the Company's Term Loan Agreement; Company made $100M voluntary prepayment in late December 2025.","start_date":null},{"partner_name":"BARDA","partnership_type":"development","description":"Received contract option valued at ~$16.7M to continue post-licensure development collaboration activities for Ebanga.","start_date":null}],"affiliations":[],"origin":{"leaf":"c98fffda2c5da9d8db8ec3c0539678dc0eaef2a5ea121a8d09538a67921525e8","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a4eae436cebd1a37ee219b8ea7ed3cd4b1eb54f045acb1001c48c60cdda5286f","parent":"63086f0ca3e1a1a2168a8dfe909584e887243ba9a2fb2443de971786d83c0cbc","source":"0001367644-26-000015","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":202,"hourly_limit":500,"remaining":298,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}